BRPI0821115A2 - Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto - Google Patents
Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do compostoInfo
- Publication number
- BRPI0821115A2 BRPI0821115A2 BRPI0821115-9A BRPI0821115A BRPI0821115A2 BR PI0821115 A2 BRPI0821115 A2 BR PI0821115A2 BR PI0821115 A BRPI0821115 A BR PI0821115A BR PI0821115 A2 BRPI0821115 A2 BR PI0821115A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- aminotriazole
- drug
- pharmaceutical composition
- derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2007055199 | 2007-12-18 | ||
IB2008054369 | 2008-10-23 | ||
PCT/IB2008/055375 WO2009077990A1 (en) | 2007-12-18 | 2008-12-17 | Aminotriazole derivatives as alx agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0821115A2 true BRPI0821115A2 (pt) | 2015-06-16 |
BRPI0821115A8 BRPI0821115A8 (pt) | 2017-12-26 |
Family
ID=40404773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0821115A BRPI0821115A8 (pt) | 2007-12-18 | 2008-12-17 | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto |
Country Status (26)
Country | Link |
---|---|
US (1) | US8536209B2 (pt) |
EP (1) | EP2225231B1 (pt) |
JP (1) | JP4656674B2 (pt) |
KR (1) | KR101213007B1 (pt) |
CN (1) | CN101903378B (pt) |
AR (1) | AR069801A1 (pt) |
AT (1) | ATE520689T1 (pt) |
AU (1) | AU2008337097B2 (pt) |
BR (1) | BRPI0821115A8 (pt) |
CA (1) | CA2706839C (pt) |
CY (1) | CY1112465T1 (pt) |
DK (1) | DK2225231T3 (pt) |
HK (1) | HK1144158A1 (pt) |
HR (1) | HRP20110825T1 (pt) |
IL (1) | IL206399A (pt) |
MA (1) | MA31949B1 (pt) |
MX (1) | MX2010006241A (pt) |
MY (1) | MY153985A (pt) |
NZ (1) | NZ586735A (pt) |
PL (1) | PL2225231T3 (pt) |
PT (1) | PT2225231E (pt) |
RU (1) | RU2492167C2 (pt) |
SI (1) | SI2225231T1 (pt) |
TW (1) | TWI434685B (pt) |
WO (1) | WO2009077990A1 (pt) |
ZA (1) | ZA201005080B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
TWI490190B (zh) * | 2009-05-18 | 2015-07-01 | Actelion Pharmaceuticals Ltd | 橋聯螺〔2.4〕庚烷衍生物 |
RU2544862C2 (ru) | 2009-06-09 | 2015-03-20 | Актелион Фармасьютиклз Лтд | Фторированные аминотриазольные производные |
WO2010143158A1 (en) | 2009-06-12 | 2010-12-16 | Actelion Pharmaceuticals Ltd | Oxazole and thiazole derivatives as alx receptor agonists |
WO2012066488A2 (en) | 2010-11-17 | 2012-05-24 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
EP2649068B1 (en) * | 2010-12-07 | 2014-10-29 | Actelion Pharmaceuticals Ltd. | Oxazolyl-methylether derivatives as alx receptor agonists |
TW201305150A (zh) | 2010-12-07 | 2013-02-01 | Actelion Pharmaceuticals Ltd | 作為脂氧素(alx)受體激動劑之羥基化胺基三唑衍生物 |
EP2707373A1 (de) | 2011-05-10 | 2014-03-19 | Bayer Intellectual Property GmbH | Bicyclische (thio)carbonylamidine |
WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
CN102558117B (zh) * | 2011-12-15 | 2014-10-08 | 北京金骄生物质化工有限公司 | 一种利用废弃生物质制备5-硝基-2-糠酸酯的方法 |
JP6101788B2 (ja) | 2012-05-16 | 2017-03-22 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | ALX受容体アゴニストとしての1−(p−トリル)シクロプロピル置換架橋スピロ[2.4]ヘプタン誘導体 |
MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
AU2013273222B2 (en) | 2012-06-04 | 2017-11-02 | Idorsia Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
CA2885180C (en) | 2012-10-10 | 2021-03-02 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
RU2015123982A (ru) * | 2012-12-03 | 2017-01-13 | Ф. Хоффманн-Ля Рош Аг | Соединения замещенных триазола и имидазола |
EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
CA2915757A1 (en) | 2013-07-18 | 2015-01-22 | Actelion Pharmaceuticals Ltd | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
TN2016000210A1 (en) | 2013-11-28 | 2017-10-06 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof. |
CA2930053A1 (en) | 2013-12-04 | 2015-06-11 | Actelion Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
EA201792382A1 (ru) | 2015-05-27 | 2018-04-30 | Киорин Фармасютикал Ко., Лтд. | Производное мочевины или его фармакологически приемлемая соль |
US10858314B2 (en) | 2015-05-27 | 2020-12-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
EA201891007A1 (ru) * | 2015-11-24 | 2018-11-30 | Бристол-Маерс Сквибб Компани | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца |
KR20200128709A (ko) | 2018-03-05 | 2020-11-16 | 브리스톨-마이어스 스큅 컴퍼니 | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 |
US11629143B2 (en) | 2020-10-01 | 2023-04-18 | Vibliome Therapeutics, Llc | HipK4 inhibitors and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62234018A (ja) | 1986-04-02 | 1987-10-14 | Rooto Seiyaku Kk | 糖尿病併発症治療剤 |
AU2002359311A1 (en) | 2001-10-26 | 2003-05-06 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health An | Amyloid ss is a ligand for fpr class receptors |
WO2003082314A2 (en) | 2002-04-03 | 2003-10-09 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
BRPI0416272A (pt) | 2003-11-07 | 2007-01-09 | Acadia Pharm Inc | usos do receptor fprl1, e de compostos, uso profilático de compostos, métodos de triagem para um composto capaz de afetar uma ou mais atividades de um receptor fprl1, de tratamento ou prevenção de inflamação, de identificação de um composto de indução de vasodilatação, para antagonismo de uma resposta vasoconstrutiva a um sulfidopeptìdeo leucotrieno em um indivìduo, e para estimulação de proliferação celular em um indivìduo, e, composto |
CN1997633A (zh) * | 2004-05-25 | 2007-07-11 | 麦它波莱克斯股份有限公司 | 作为ppar调节剂的取代的三唑及其制备方法 |
DE602005019093D1 (de) * | 2004-12-13 | 2010-03-11 | Leo Pharma As | Triazolsubstituierte aminobenzophenonverbindungen |
AU2006312083A1 (en) | 2005-11-03 | 2007-05-18 | Merck Sharp & Dohme Corp. | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
US7998978B2 (en) * | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
ES2545121T3 (es) | 2007-08-21 | 2015-09-08 | Senomyx, Inc. | Compuestos que inhiben (bloquean) el sabor amargo en composiciones, y uso de los mismos |
AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
TWI490190B (zh) | 2009-05-18 | 2015-07-01 | Actelion Pharmaceuticals Ltd | 橋聯螺〔2.4〕庚烷衍生物 |
RU2544862C2 (ru) | 2009-06-09 | 2015-03-20 | Актелион Фармасьютиклз Лтд | Фторированные аминотриазольные производные |
WO2010143158A1 (en) | 2009-06-12 | 2010-12-16 | Actelion Pharmaceuticals Ltd | Oxazole and thiazole derivatives as alx receptor agonists |
-
2008
- 2008-12-17 NZ NZ586735A patent/NZ586735A/en not_active IP Right Cessation
- 2008-12-17 SI SI200830412T patent/SI2225231T1/sl unknown
- 2008-12-17 TW TW097149199A patent/TWI434685B/zh not_active IP Right Cessation
- 2008-12-17 EP EP08862134A patent/EP2225231B1/en not_active Not-in-force
- 2008-12-17 RU RU2010129272/04A patent/RU2492167C2/ru not_active IP Right Cessation
- 2008-12-17 AU AU2008337097A patent/AU2008337097B2/en not_active Ceased
- 2008-12-17 MY MYPI2010002834A patent/MY153985A/en unknown
- 2008-12-17 JP JP2010539015A patent/JP4656674B2/ja not_active Expired - Fee Related
- 2008-12-17 CA CA2706839A patent/CA2706839C/en not_active Expired - Fee Related
- 2008-12-17 DK DK08862134.7T patent/DK2225231T3/da active
- 2008-12-17 AT AT08862134T patent/ATE520689T1/de active
- 2008-12-17 US US12/809,545 patent/US8536209B2/en not_active Expired - Fee Related
- 2008-12-17 CN CN200880122188.XA patent/CN101903378B/zh not_active Expired - Fee Related
- 2008-12-17 PL PL08862134T patent/PL2225231T3/pl unknown
- 2008-12-17 WO PCT/IB2008/055375 patent/WO2009077990A1/en active Application Filing
- 2008-12-17 BR BRPI0821115A patent/BRPI0821115A8/pt not_active IP Right Cessation
- 2008-12-17 KR KR1020107015871A patent/KR101213007B1/ko not_active IP Right Cessation
- 2008-12-17 MX MX2010006241A patent/MX2010006241A/es active IP Right Grant
- 2008-12-17 PT PT08862134T patent/PT2225231E/pt unknown
- 2008-12-18 AR ARP080105522A patent/AR069801A1/es not_active Application Discontinuation
-
2010
- 2010-06-16 IL IL206399A patent/IL206399A/en not_active IP Right Cessation
- 2010-06-29 MA MA32968A patent/MA31949B1/fr unknown
- 2010-07-16 ZA ZA2010/05080A patent/ZA201005080B/en unknown
- 2010-11-18 HK HK10110770.3A patent/HK1144158A1/xx not_active IP Right Cessation
-
2011
- 2011-11-10 HR HR20110825T patent/HRP20110825T1/hr unknown
- 2011-11-17 CY CY20111101111T patent/CY1112465T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
BRPI0810696A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0919942A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0907562A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0921375A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0810161A2 (pt) | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto | |
BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
BRPI0917315A2 (pt) | anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica | |
BRPI0912717A2 (pt) | Composição farmacêutica, e, uso de 5-azacitidina | |
BRPI0921879A2 (pt) | composto, composição farmacêutica , e, uso de um composto | |
BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0716171A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto. | |
BRPI0917579A2 (pt) | composto, composição farmacêutica, métodos, e, uso de um composto | |
BRPI0821301A2 (pt) | Composto de aspirinato de isossorbida, composto carregador, composto medicamentoso, composição farmacêutica, e, uso de um composto | |
BRPI0810019A2 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0917001A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica | |
BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
BRPI0812942A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
BRPI0915120A2 (pt) | composto derivado de oxima, uso do referido composto e composição farmacêutica | |
BRPI0906937A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
BRPI0716698A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
BRPI0915473A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0919165A2 (pt) | composição farmacêutica,e, uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B25C | Requirement related to requested transfer of rights |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |